{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cetuximab&page=22", "query": { "intervention": "cetuximab", "page": 22 }, "page_size": 10 }, "pagination": { "page": 22, "page_size": 10, "total_count": 559, "total_pages": 56, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cetuximab&page=23&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cetuximab&page=21&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T01:42:32.244Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00226941", "title": "A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Rectal Cancer", "Colo-rectal Cancer" ], "interventions": [ { "name": "Cetuximab", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Radiotherapy", "type": "RADIATION" }, { "name": "Diphenhydramine hydrochloride (HCl)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "George Albert Fisher", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2004-06", "completion_date": "2009-02", "has_results": true, "last_update_posted_date": "2017-12-08", "last_synced_at": "2026-10-29T01:42:32.244Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00226941" }, { "nct_id": "NCT05863195", "title": "Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Colorectal Carcinoma", "Metastatic Malignant Neoplasm in the Liver", "Stage IV Colorectal Cancer AJCC v8", "Unresectable Colorectal Carcinoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Floxuridine", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Implantation", "type": "PROCEDURE" }, { "name": "Intrahepatic Infusion Procedure", "type": "PROCEDURE" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Panitumumab", "type": "BIOLOGICAL" }, { "name": "Single Photon Emission Computed Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 408, "start_date": "2024-04-10", "completion_date": "2029-06-30", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-29T01:42:32.244Z", "location_count": 62, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 48 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05863195" }, { "nct_id": "NCT00326911", "title": "Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "gemcitabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2006-05", "completion_date": "2008-12", "has_results": true, "last_update_posted_date": "2011-05-25", "last_synced_at": "2026-10-29T01:42:32.244Z", "location_count": 16, "location_summary": "Jonesboro, Arkansas • San Francisco, California • Stamford, Connecticut + 12 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "San Francisco", "state": "California" }, { "city": "Stamford", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00326911" }, { "nct_id": "NCT00898742", "title": "Gene and Protein Expression Patterns in Predicting Response to Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "DNA and tissue microarray analysis", "type": "GENETIC" }, { "name": "reverse transcriptase-polymerase chain reaction", "type": "GENETIC" }, { "name": "mass spectrometry", "type": "OTHER" } ], "intervention_types": [ "GENETIC", "OTHER" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 58, "start_date": "2007-04", "completion_date": "2010-06", "has_results": false, "last_update_posted_date": "2013-04-02", "last_synced_at": "2026-10-29T01:42:32.244Z", "location_count": 3, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00898742" }, { "nct_id": "NCT00096031", "title": "S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "cetuximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 63, "start_date": "2004-10", "completion_date": "2010-01", "has_results": true, "last_update_posted_date": "2018-09-26", "last_synced_at": "2026-10-29T01:42:32.244Z", "location_count": 152, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 104 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Castro Valley", "state": "California" }, { "city": "Hayward", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00096031" }, { "nct_id": "NCT00466505", "title": "Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "celecoxib", "type": "DRUG" }, { "name": "proteomic profiling", "type": "GENETIC" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "mass spectrometry", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "GENETIC", "OTHER" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2005-05", "completion_date": "2008-11", "has_results": true, "last_update_posted_date": "2012-12-19", "last_synced_at": "2026-10-29T01:42:32.244Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00466505" }, { "nct_id": "NCT04616183", "title": "LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Colon Adenocarcinoma", "Metastatic Colorectal Carcinoma", "Metastatic Rectal Adenocarcinoma", "Recurrent Colorectal Carcinoma", "Stage III Colon Cancer AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage III Rectal Cancer AJCC v8", "Stage IIIA Colon Cancer AJCC v8", "Stage IIIA Colorectal Cancer AJCC v8", "Stage IIIA Rectal Cancer AJCC v8", "Stage IIIB Colon Cancer AJCC v8", "Stage IIIB Colorectal Cancer AJCC v8", "Stage IIIB Rectal Cancer AJCC v8", "Stage IIIC Colon Cancer AJCC v8", "Stage IIIC Colorectal Cancer AJCC v8", "Stage IIIC Rectal Cancer AJCC v8", "Stage IV Colon Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Rectal Cancer AJCC v8", "Stage IVA Colon Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVA Rectal Cancer AJCC v8", "Stage IVB Colon Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVB Rectal Cancer AJCC v8", "Stage IVC Colon Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8", "Stage IVC Rectal Cancer AJCC v8", "Unresectable Colon Adenocarcinoma", "Unresectable Colorectal Carcinoma", "Unresectable Rectal Adenocarcinoma" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "ERK1/2 Inhibitor LY3214996", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2020-12-02", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-29T01:42:32.244Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04616183" }, { "nct_id": "NCT00716456", "title": "Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed \"Acquired Resistance\" to Erlotinib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Adenocarcinoma" ], "interventions": [ { "name": "erlotinib with cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2008-07", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2015-04-30", "last_synced_at": "2026-10-29T01:42:32.244Z", "location_count": 5, "location_summary": "Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Rockville Centre", "state": "New York" }, { "city": "Sleepy Hollow", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00716456" }, { "nct_id": "NCT04966481", "title": "Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HPV-unrelated Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Palbociclib", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 81, "start_date": "2022-04-06", "completion_date": "2029-02-28", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-29T01:42:32.244Z", "location_count": 5, "location_summary": "Worthington, Minnesota • Kansas City, Missouri • St Louis, Missouri + 2 more", "locations": [ { "city": "Worthington", "state": "Minnesota" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Fargo", "state": "North Dakota" }, { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04966481" }, { "nct_id": "NCT07702032", "title": "Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Left-sided Colorectal Cancer" ], "interventions": [ { "name": "Petosemtamab", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "mFOLFOX6", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 960, "start_date": "2026-08-11", "completion_date": "2031-09", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-29T01:42:32.244Z", "location_count": 7, "location_summary": "Hot Springs, Arkansas • Los Angeles, California • Savannah, Georgia + 4 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Savannah", "state": "Georgia" }, { "city": "Warner Robins", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT07702032" } ] }